Israel Active

Aziz Kaddan and Anas Abu Mukh began degree courses at Haifa University when they were 16 years old.  They were just 19 when they thought up Myndlift - an app that teaches ADHD children and adults to concentrate by using their brainwaves to display a bright image.

A team of Israeli and Japanese researchers has embarked on a project to discover how autistic spectrum disorder develops in the brain. It follows the conference “Advances in Brain Sciences”, jointly hosted by the Weizmann Institute of Science and Japan’s RIKEN Brain Science Institute.

Hebrew University of Jerusalem researchers have discovered that neutrophils (a form of white blood cell) contain many different subtypes. Some of these prevent cancer and others promote it. It opens avenues for therapies that increase anti-tumor neutrophils and limit pro-tumor ones.

(Thanks to Israel21c) Norway’s largest charitable organization, the Olav Thon Foundation has chosen Tel Aviv University cancer geneticist Professor Yosef Shiloh as one of the two recipients of its very first international medical research award.

Israel’s Health Council has added an additional 73 medicines and technologies into the Government’s subsidized “Health Basket”.  The changes will benefit 350,000 Israelis at a cost of NIS 324 million.  

Scientists at the Hebrew University of Jerusalem are studying brain activity of blind people in order to shed new light on how our brains can adpt to the rapid cultural and technological changes of the 21st Century.  Already they have found that reading Braille utilizes “visual” areas of the brain.

A 35-year-old study by Israel’s Professor Raphael Mechoulam convinced Denver-based physician Dr. Alan Shackelford to use synthesized cannabidiol or CBD to save 5-year-old Charlotte Figi who suffered 300 epileptic fits a week.  Dr Shackelford immigrated to Israel in 2012.

Israel’s Fruitful Way Ltd. has pioneered a new, natural fertility and conception toolkit for couples who are trying to get pregnant. It includes a unique, science-backed dietary supplement, scientifically mated with a sophisticated fertility app.

(Thanks to Atid-EDI) Israel’s Teva has launched the first FDA-approved generic equivalent to Celebrex (Celecoxib) Capsules in the US.  Celebrex is used to treat arthritis, pain, menstrual cramps, and colonic polyps.

Israel’s Protalix Biotherepeutics reported good results in its trials of its PRX-102 treatment for the genetic disease Fabry’s.  Even a low dosage had an average 78.8% decrease in the effect of pain on the patients' functioning.